Anti-interleukin-2 receptor antibodies:: basiliximab and dactizumab

被引：32

作者：

Pascual, J ^{[1
]}

Marcén, R ^{[1
]}

Ortuño, J ^{[1
]}

机构：

[1] Univ Alcala de Henares, Hosp Ramon & Cajal, Serv Nefrol, E-28034 Madrid, Spain

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2001年 / 16卷 / 09期

关键词：

basiliximab; daclizumab; monoclonal antibodies;

D O I：

10.1093/ndt/16.9.1756

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

[No abstract available]

引用

页码：1756 / 1760

页数：5

共 31 条

[1]

Ahmad I, 2000, TRANSPLANTATION, V69, pS159

[2] PROLONGED ACTION OF A CHIMERIC INTERLEUKIN-2 RECEPTOR (CD25) MONOCLONAL-ANTIBODY USED IN CADAVERIC RENAL-TRANSPLANTATION [J].

AMLOT, PL ;

RAWLINGS, E ;

FERNANDO, ON ;

GRIFFIN, PJ ;

HEINRICH, G ;

SCHREIER, MH ;

CASTAIGNE, JP ;

MOORE, R ;

SWENY, P .

TRANSPLANTATION, 1995, 60 (07) :748-756

[3] ANTI-TAC-H, A HUMANIZED ANTIBODY TO THE INTERLEUKIN-2 RECEPTOR, PROLONGS PRIMATE CARDIAC ALLOGRAFT SURVIVAL [J].

BROWN, PS ;

PARENTEAU, GL ;

DIRBAS, FM ;

GARSIA, RJ ;

GOLDMAN, CK ;

BUKOWSKI, MA ;

JUNGHANS, RP ;

QUEEN, C ;

HAKIMI, J ;

BENJAMIN, WR ;

CLARK, RE ;

WALDMANN, TA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (07) :2663-2667

[4] One or two doses of daclizumab provide effective immunosuppression for renal transplant patients with high immunologic risk or with delayed graft function. [J].

Chang, GJ ;

O Rourke, R ;

Lee, I ;

Stock, PG ;

Vincenti, F .

TRANSPLANTATION, 1999, 67 (07) :S149-S149

[5]

Deierhoi MH, 2000, TRANSPLANTATION, V69, pS260

[6]

Felipe C, 2000, NEFROLOGIA, V20, P8

[7]

Flechner SM, 2000, TRANSPLANTATION, V69, pS157

[8]

Golconda MS, 2000, TRANSPLANTATION, V69, pS158

[9]

Grinyó JM, 2000, NEFROLOGIA, V20, P59

[10] Cancer risk associated with ATG/OKT3 in renal transplantation [J].

Hibberd, AD ;

Trevillian, PR ;

Wlodarzcyk, JH ;

Gillies, AHB ;

Stein, AM ;

Sheil, AGR ;

Disney, APS .

TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) :1271-1272

← 1 2 3 4 →